We recently compiled a list of the 10 Overlooked Healthcare Stocks to Invest in. Jazz Pharmaceuticals plc is one of them.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a specialty pharmaceutical company focused on neuroscience, oncology, and rare diseases, with a global presence and products including Xywav and Epidiolex.
In August 2025, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) received FDA accelerated approval for Modeyso™ (dordaviprone), the first therapy for adult and pediatric patients with recurrent diffuse midline glioma carrying the H3 K27M mutation. This breakthrough addresses a critical unmet need in an aggressive brain cancer and represents a strategic expansion beyond the company’s legacy sleep disorder portfolio. The corporation plans an investor webcast on August 27, 2025, to present clinical data and commercialization strategy for Modeyso™.
The business also presented late-breaking clinical data at SLEEP 2025, including Phase 4 results for Xywav in narcolepsy, survival data for Ziihera in HER2-positive biliary tract cancer, and combination therapy data for Zepzelca with Tecentriq in small cell lung cancer, showing meaningful survival benefits.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will participate in the 2025 Wells Fargo Healthcare Conference in September to discuss pipeline progress and strategic plans.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
